Surrozen (NASDAQ:SRZN) Issues Quarterly Earnings Results, Beats Expectations By $1.25 EPS

Surrozen (NASDAQ:SRZN) posted its quarterly earnings results on Monday. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.79) by $1.25, Zacks reports.

Surrozen Trading Down 10.1 %

SRZN traded down $0.74 during trading on Wednesday, hitting $6.56. The company had a trading volume of 41,302 shares, compared to its average volume of 13,319. The business has a 50-day moving average of $9.47 and a 200-day moving average of $10.53. Surrozen has a 1-year low of $4.50 and a 1-year high of $16.19.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.